Core Viewpoint - Spring Medical (688236) shows significant growth in revenue and net profit for the first three quarters of 2025, indicating strong operational performance and potential investment interest [3]. Financial Performance - For the first three quarters of 2025, Spring Medical reported a main revenue of 756 million yuan, a year-on-year increase of 48.75% [3]. - The net profit attributable to shareholders reached 192 million yuan, up 213.21% year-on-year [3]. - The net profit excluding non-recurring items was 181 million yuan, reflecting a substantial increase of 311.07% year-on-year [3]. - In Q3 2025 alone, the company achieved a main revenue of 268 million yuan, a remarkable increase of 109.51% year-on-year [3]. - The quarterly net profit attributable to shareholders was 77.06 million yuan, showing a significant rise of 531.12% year-on-year [3]. - The quarterly net profit excluding non-recurring items was 74.52 million yuan, up 439.4% year-on-year [3]. - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan [3]. - The gross profit margin is reported at 67.27% [3]. Market Activity - As of December 19, 2025, Spring Medical's stock closed at 24.84 yuan, reflecting a 3.76% increase [1]. - The trading volume on December 19 was 17,800 hands, with a total transaction amount of 44.1792 million yuan [1]. - The net inflow of main funds was 219,000 yuan, accounting for 0.5% of the total transaction amount, while retail investors saw a net inflow of 251,610 yuan, representing 5.7% of the total [1]. - Over the past five days, the financing buy amounted to 1.558 million yuan, while financing repayment was 2.6855 million yuan, resulting in a net repayment of 1.1275 million yuan [2]. - The financing and securities balance is reported at 31.0494 million yuan [2]. Analyst Ratings - In the last 90 days, 9 institutions have rated Spring Medical, with 8 giving a "buy" rating and 1 an "increase" rating [3]. - The average target price set by institutions over the past 90 days is 31.8 yuan [3].

Core Viewpoint - The Hong Kong stock market has shown significant gains, with several companies experiencing notable increases in their stock prices on December 19, 2023 [1][2]. Group 1: Stock Performance - Zhihui Mining (02546.HK) saw the highest increase, rising by 135.48% to a price of 10.62 [1][2]. - Huan Da Fu Holdings (01348.HK) increased by 21.21%, reaching a price of 0.24 [1][2]. - Likou Health Life (02370.HK) experienced a rise of 14.12%, with its stock priced at 0.48 [1][2]. - Ocean Group (01991.HK) rose by 14.08%, with a current price of 0.81 [1][2]. - CHI HO DEV (08423.HK) increased by 13.04%, priced at 0.0526 [1][2]. - Huameilele (08429.HK) saw an increase of 11.29%, with a stock price of 0.0697 [1][2]. - Chunli Medical (01858.HK) rose by 7.31%, reaching a price of 16.45 [1][2]. - Saint Tang Holdings (08305.HK) increased by 7.04%, with a stock price of 0.38 [1][2]. - Star Tai Chain Group (00399.HK) saw a rise of 6.38%, priced at 0.1 [1][2]. - Southern Double Short Coinbase (07311.HK) increased by 6.09%, with a current price of 13.06 [1][2].

Group 1 - The core viewpoint of the article highlights the financial performance and stock activity of Chunli Medical (688236) as of December 18, 2025, showing a slight decline in stock price and mixed capital flow [1][2] - Chunli Medical reported a main revenue of 756 million yuan for the first three quarters of 2025, representing a year-on-year increase of 48.75% [2] - The net profit attributable to shareholders for the same period was 192 million yuan, up 213.21% year-on-year, with a non-recurring net profit of 181 million yuan, increasing by 311.07% [2] Group 2 - In Q3 2025, Chunli Medical achieved a single-quarter main revenue of 268 million yuan, reflecting a year-on-year growth of 109.51% [2] - The single-quarter net profit attributable to shareholders was 77.06 million yuan, marking a significant increase of 531.12% year-on-year, while the non-recurring net profit reached 74.52 million yuan, up 439.4% [2] - The company's debt ratio stands at 15.65%, with investment income of 3.217 million yuan and financial expenses of -9.7234 million yuan, alongside a gross margin of 67.27% [2] Group 3 - The stock has received ratings from 9 institutions in the last 90 days, with 8 buy ratings and 1 hold rating, and the average target price set at 31.8 yuan [2] - On December 18, 2025, the stock closed at 23.94 yuan, with a turnover rate of 0.32% and a trading volume of 9143 hands, resulting in a transaction amount of 21.97 million yuan [1] - The capital flow data indicates a net outflow of 1.1464 million yuan from main funds, accounting for 5.22% of the total transaction amount, while retail investors saw a net inflow of 2.0827 million yuan, representing 9.48% of the total [1]

Group 1 - The core viewpoint of the article highlights the performance of the Shanghai Composite Index and the Hang Seng Index, with the former rising by 0.16% to close at 3876.37 points and the latter increasing by 0.12% to close at 25498.13 points [1] - Spring Medical's A/H share premium reached 72.56%, ranking 54th among A/H shares, with the A-share closing at 23.94 yuan, down 0.33%, and the H-share at 15.33 HKD, down 0.2% [1] - Founded in 1998, Beijing Spring Medical Device Co., Ltd. (688236.SH+01858.HK) focuses on the continuous development and research of high-end medical devices, covering a full range of orthopedic products including joint, spine, sports medicine, and trauma categories [1] Group 2 - The company holds 124 medical device registration certificates and filings, enhancing its product line and expanding its presence in the medical field to meet diverse market and clinical needs, thereby improving overall competitiveness [1] - While maintaining a leading position in the domestic market, the company is actively exploring international markets, with its products exported to over 50 countries and regions worldwide [1]

证券之星消息，截至2025年12月16日收盘，春立医疗(688236)报收于23.77元，下跌0.75%，换手率 0.29%，成交量8329.0手，成交额1976.42万元。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 12月16日的资金流向数据方面，主力资金净流出220.45万元，占总成交额11.15%，游资资金净流入 119.97万元，占总成交额6.07%，散户资金净流入100.48万元，占总成交额5.08%。 近5日资金流向一览见下表： 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比 ...

Core Viewpoint - The Shenzhen-Hong Kong Stock Connect Medical Index (港币) closed at 4287.1 points, down 0.23%, with a trading volume of 7.011 billion yuan and a turnover rate of 0.72% [1] Group 1: Index Performance - On the day, 18 constituent stocks rose, with Blue Sail Medical leading with a 10.0% increase, while 36 stocks declined, with Yimai Sunshine leading the decline at 3.83% [1] - The net outflow of main funds from the Shenzhen-Hong Kong Stock Connect Medical Index constituents totaled 115 million yuan, while retail investors saw a net inflow of 181 million yuan [1] Group 2: Constituent Stocks Details - The top ten constituent stocks of the Shenzhen-Hong Kong Stock Connect Medical Index include: - Yimai Sunshine (hk02522) with a market cap of 3.43 billion yuan and a price drop of 3.83% [1] - Weikang Medical (hk00853) with a market cap of 17.4 billion yuan and a price drop of 3.38% [1] - Weikang Robotics (hk02252) with a market cap of 19.21 billion yuan and a price drop of 2.84% [1] - Wu Hai Biotechnology (hk06826) with a market cap of 5.46 billion yuan and a price drop of 2.27% [1] - Dian Diagnostics (sz300244) with a market cap of 9.19 billion yuan and a price drop of 2.13% [1] - Ruimaite (sz301367) with a market cap of 7.59 billion yuan and a price drop of 2.08% [1] - Tuya Holdings (hk01099) with a market cap of 56.54 billion yuan and a price drop of 1.96% [1] - Yidu Technology (hk02158) with a market cap of 4.83 billion yuan and a price drop of 1.96% [1] - Xintai Medical (hk02291) with a market cap of 5.23 billion yuan and a price drop of 1.83% [1] - Chunli Medical (hk01858) with a market cap of 5.26 billion yuan and a price drop of 1.76% [1]

来源：新浪证券-红岸工作室 12月15日，春立医疗涨1.05%，成交额3236.17万元，换手率0.47%，总市值91.86亿元。 异动分析 医疗器械概念+智能医疗+牙科医疗+专精特新+京津冀一体化 今日主力净流入-77.53万，占比0.02%，行业排名85/132，连续2日被主力资金减仓；所属行业主力净流 入95.76万，连续2日被主力资金增仓。 区间今日近3日近5日近10日近20日主力净流入-77.53万-271.29万-506.40万-1128.50万-2068.68万 2、2024年10月9日互动易：我公司是一家专注于骨科医疗器械领域的高新技术企业，产品涵盖关节类、 脊柱类、运动医学类、创伤类等全系列骨科产品。同时公司已经取得了髋关节手术机器人、膝关节手术 机器人等产品的注册证，以及手术规划的"医学图像处理软件"。这些产品和软件的开发表明公司在智能 医疗等领域进行的布局和研发投入。 3、国内领先的骨科医疗器械厂商，春立医疗主营业务系植入性骨科医疗器械的研发、生产与销售，包 括口腔金属和隐形正畸 口腔种植和修复。 公司拟设计多孔钽定制个体化牙种植体产品并完成生产转 换， 目前处于设计送检阶段。 4、专精 ...

证券之星消息，截至2025年12月12日收盘，春立医疗(688236)报收于23.7元，下跌1.13%，换手率 0.38%，成交量1.09万手，成交额2612.12万元。 春立医疗2025年三季报显示，前三季度公司主营收入7.56亿元，同比上升48.75%；归母净利润1.92亿 元，同比上升213.21%；扣非净利润1.81亿元，同比上升311.07%；其中2025年第三季度，公司单季度主 营收入2.68亿元，同比上升109.51%；单季度归母净利润7706.19万元，同比上升531.12%；单季度扣非 净利润7451.86万元，同比上升439.4%；负债率15.65%，投资收益321.7万元，财务费用-972.34万元，毛 利率67.27%。春立医疗（688236）主营业务：植入性骨科医疗器械的研发、生产与销售。 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为 31.8。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股 ...

Group 1 - The top short-selling ratios are led by China Resources Beer (80291), AIA Insurance (81299), and Anta Sports (82020), all at 100.00% [1][2] - The highest short-selling amounts are recorded for Alibaba (09988) at 1.485 billion, Tencent Holdings (00700) at 1.163 billion, and China Construction Bank (00939) at 921 million [1][2] - The highest deviation values are for China Resources Beer (80291) at 37.08%, AIA Insurance (81299) at 34.84%, and Spring Health (01858) at 34.29% [1][2] Group 2 - The top ten short-selling ratios include JD Health (86618) at 100.00%, SenseTime (80020) at 89.60%, and Lenovo Group (80992) at 87.78% [2] - The top ten short-selling amounts also feature Xiaomi Group (01810) at 914 million and Pop Mart (09992) at 826 million [2] - The top ten short-selling deviation values include Baidu Group (89888) at 32.64% and Yum China (09987) at 29.58% [2]

证券之星消息，截至2025年12月10日收盘，春立医疗(688236)报收于24.1元，上涨1.01%，换手率 0.27%，成交量7793.0手，成交额1870.21万元。 12月10日的资金流向数据方面，主力资金净流出277.84万元，占总成交额14.86%，游资资金净流入 26.57万元，占总成交额1.42%，散户资金净流入251.27万元，占总成交额13.44%。 近5日资金流向一览见下表： 该股最近90天内共有8家机构给出评级，买入评级7家，增持评级1家；过去90天内机构目标均价为 31.8。 资金流向名词解释：指通过价格变化反推资金流向。股价处于上升状态时主动性买单形成的成交额是推 动股价上涨的力量，这部分成交额被定义为资金流入，股价处于下跌状态时主动性卖单产生的的成交额 是推动股价下跌的力量，这部分成交额被定义为资金流出。当天两者的差额即是当天两种力量相抵之后 剩下的推动股价上升的净力。通过逐笔交易单成交金额计算主力资金流向、游资资金流向和散户资金流 向。 注：主力资金为特大单成交，游资为大单成交，散户为中小单成交 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710 ...